Literature DB >> 16034480

JAK/STAT-dependent gene regulation by cytokines.

D Hebenstreit1, J Horejs-Hoeck, A Duschl.   

Abstract

The Janus kinase-signal transducer and activator of transcription (Jak-STAT) pathway is essential for the signal transduction of many cytokines. Dysregulation of Jak-STAT signaling is associated with various human diseases. Recent studies have helped to shed some light on regulatory mechanisms that modify quantity and quality of the signaling response. Here, we summarize our current knowledge on Jak-STAT signaling. 2005 Prous Science. All rights reserved

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034480     DOI: 10.1358/dnp.2005.18.4.908658

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  29 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

2.  Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells.

Authors:  Qin Yuan; Pin Dong Li; Ben Hui Li; Xian Zi Yang; Shuang Bing Xu; Xiao Hong Liu; Fu Xiang Zhou; Wen Jie Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-07       Impact factor: 4.553

3.  Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.

Authors:  Kleiton Augusto Santos Silva; Jiangling Dong; Yanjun Dong; Yanlan Dong; Nestor Schor; David J Tweardy; Liping Zhang; William E Mitch
Journal:  J Biol Chem       Date:  2015-03-18       Impact factor: 5.157

4.  Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2.

Authors:  Fong-Fong Chu; R Steven Esworthy; Binghui Shen; Qiang Gao; James H Doroshow
Journal:  Life Sci       Date:  2019-11-02       Impact factor: 5.037

5.  RNA-seq-based transcriptome profiling reveals differential gene expression in the lungs of Sprague-Dawley rats during early-phase acute hypobaric hypoxia.

Authors:  Priyanka Sharma; Anju Bansal; Prakash Chand Sharma
Journal:  Mol Genet Genomics       Date:  2015-06-07       Impact factor: 3.291

6.  Gene expression profiling identifies genes predictive of oral squamous cell carcinoma.

Authors:  Chu Chen; Eduardo Méndez; John Houck; Wenhong Fan; Pawadee Lohavanichbutr; Dave Doody; Bevan Yueh; Neal D Futran; Melissa Upton; D Gregory Farwell; Stephen M Schwartz; Lue Ping Zhao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-31       Impact factor: 4.254

7.  BCL6 controls Th9 cell development by repressing Il9 transcription.

Authors:  Ribal Bassil; William Orent; Marta Olah; Ahmed T Kurdi; Michael Frangieh; Thomas Buttrick; Samia J Khoury; Wassim Elyaman
Journal:  J Immunol       Date:  2014-05-30       Impact factor: 5.422

8.  Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.

Authors:  Rui-Ru Ji; Heshani de Silva; Yisheng Jin; Robert E Bruccoleri; Jian Cao; Aiqing He; Wenjun Huang; Paul S Kayne; Isaac M Neuhaus; Karl-Heinz Ott; Becky Penhallow; Mark I Cockett; Michael G Neubauer; Nathan O Siemers; Petra Ross-Macdonald
Journal:  PLoS Comput Biol       Date:  2009-09-18       Impact factor: 4.475

9.  Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.

Authors:  Haiyu Li; Zhenggang Ren; Xiaonan Kang; Lan Zhang; Xuefei Li; Yan Wang; Tongchun Xue; Yuefang Shen; Yinkun Liu
Journal:  BMC Cancer       Date:  2009-10-16       Impact factor: 4.430

10.  Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid-'Ashwagandha' in Prostate Cancer Cells.

Authors:  Ravikumar Aalinkeel; Zihua Hu; Bindukumar B Nair; Donald E Sykes; Jessica L Reynolds; Supriya D Mahajan; Stanley A Schwartz
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.